Latest News
-
Rs 95/Share Dividend: Record Date On 28th June; Buy Mahindra Group Stock To Be Eligible? -
5 Bonus, Rs 28/Sh Dividend: IT Giant Infosys Beats Estimates In Q4FY24, But ADR Falls Sharply; Here's Why! -
1:10 Stock Split Approved: Small Cap Stock Issues Warrants, Shares Gain 111% YTD -
Wipro Q4 Results Preview: Weak Demand Likely To Drag Revenue Sequentially, EBIT Margins Seen Stable -
Rs 6/Share Final Dividend Declared: Buy The Blue Chip Stock To Be Eligible? -
TCS Vs Infosys: Dividend History And Upcoming Rewards, Which IT Giant Is Better? -
LIC New Jeevan Shanti 858 Plan: How To Earn Rs 10,000 Pension Per Month After Retirement? Check Eligibility! -
Kronox Lab Sciences Granted SEBI Approval to Initiate IPO -
Big News For F&O Traders! NSE To Launch Derivatives On Nifty Next 50 From April 24; Key Highlights! -
Aadhaar POI, POA Update: How To Submit Your Updated Identity, Address Proof Documents Online?
Pharma Stocks Come Crashing Down As US FDA Worries Mount
Shares in pharma companies came crashing down, as worries over US FDA concerns mounted across pharma manufacturing facilities in the country.
Similar, observations at various plants of Dr Reddy's, Sun Pharma, Lupin, Cadilla Health, Wockhardt, Cipla and IPCA Labs etc., have been received in the past.
The Nifty pharma index was down as much as 4 per cent, though the Nifty itself was trading higher. Lupin was down 11 per cent, Aurobindo Pharma fell 4 per cent and Cipla, Glenmark Pharma and Sun were down 3 per cent each.
For most of the generic pharma companies, around 60 per cent of the revenues come from the US.
The US FDA worries, hence pose a serious threat to business prospects. While many companies have received form 483, others have received warning letters from the US FDA.
Many analysts have gone ahead and downgraded pharma stocks on worries over companies hitting the US FDA wall and hence an impact on earnings.
Stocks like Lupin have been the hardest hit, with the stock falling from levels of Rs 2200 to the current level of Rs 1330.
Other stocks like Sun and Glenmark too have seen considerable price damage. Analysts say that should the US FDA problems remain, we might see further reaction in these stocks. Pharma stocks have a higher valuation compared to most other sectors, including the banking, IT or the traditional brick and mortar companies.
GoodReturns.in
